Over-treatment in the Name of Cure: Revisiting Adjuvant Therapy in the Modern Era? - Christopher Sweeney

(Length of discussion - 26 minutes) 

Christopher Sweeney, MD presents on the Over-treatment in the Name of Cure: Revisiting Adjuvant Therapy in the Modern Era? Dr. Sweeney addresses how we can cure more men from prostate cancer by taking a look at preventing relapse after definitive local therapy and radiation and hormonal therapy together vs radiation therapy alone.  He reflects on the length of time it takes to reach meaningful endpoints and the disadvantages of adjuvant therapy both of which propelled the ICECaP working group.  The group formed to develop an intermediate clinical endpoint which accurately reflects the improvement in overall survival/cure rate with using new therapies.  The group convened in 2003 to prove surrogacy of intermediate endpoint of metastasis free survival and ultimate endpoint of overall survival. Alicia Morgans joins Christopher Sweeney in reflection of the overall presentation and having the resources to accelerate the treatment progress and decrease the death rate of PCa.

Additional content on Adjuvant Therapy for Prostate Cancer

Newly Diagnosed High-Risk Disease Treatment: Summarizing Neoadjuvant Trials

Watch: Adjuvant Therapy in High-Risk Prostate Cancer after Radical Prostatectomy - Robert Bristow

AUA 2017: Postoperative Radiation Therapy for High-Risk/Locally Advanced Prostate Cancer


Christopher J. Sweeney, received his medical degree from the University of Adelaide, South Australia in 1992, and completed an internship at the Royal Adelaide Hospital. From 1994 to 1997, Dr. Sweeney was an Internal Medicine resident at Gundersen Lutheran Medical Center, La Crosse, Wisconsin, and from 1997 to 2000, he was a Fellow in Hematology/Oncology at Indiana University Medical Center. Dr. Sweeney is certified by the American Board of Internal Medicine in Medical Oncology. He has held faculty appointments at Indiana University and Royal Adelaide Hospital.

Dr. Sweeney has served on the Program Committee and the Cancer Education Committee of the American Society of Clinical Oncology and has been on the Editorial Board for ASCOs “Journal of Clinical Oncology”. He has received peer reviewed funding from the National Institutes of Health and the Department of Defense, Lance Armstrong Foundation, and PhRMA. He has also been honored to receive philanthropic support from the Shawmut Design and Construction company. He has also served on the Scientific Advisory Board of biotech companies both in Australia and USA. His research has focused on drug development and identify markers of response to therapy with a focus on prostate cancer.